Overall rank by patents
#5,176
of 49,997 tracked assignees
USPTO PatentsView assignee record - 67 granted patents across 16 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).
The verdict
According to USPTO PatentsView, Oncotherapy ranks #5,176 of 49,997 tracked US assignees by granted-patent volume, with 67 patents across 16 technology areas.
USPTO PatentsView assignee plate
Corpus R5176 · Foreign Corporation #5,176 · 67 grants
GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · VEL-DROP · BOOK-FULL
Nearest grant-volume peer: Magna Powertrain, Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Miltenyi Biotec · near
37 score
Modernsolid Industrial · near
37 score
Oncotherapy Science · this assignee
37 score
TYR Tactical · near
37 score
LG Fuel Cell Systems · near
37 score
3D Lighting… · lowest
7 score
What this shows Oncotherapy's Innovation Score is 37.1/100 (top 44% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Oncotherapy Science, Inc. is a focused PatentsView assignee: 16 CPC subclasses with 92.5% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2015 (23 grants) versus a trough of 2 in 2022. By volume, Oncotherapy sits between Magna Powertrain, Inc. and Shengyi Technology Co., Ltd..
Oncotherapy Science, Inc. shows 5 grants in 2022–2024 against only 14 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Magna Powertrain, Inc.
67 patents
Moen Incorporated
67 patents
NCS Multistage Inc.
67 patents
National University of Ireland, Galway
67 patents
Optos PLC
67 patents
Preh GmbH
67 patents
Proterra Ag, Inc.
67 patents
Shengyi Technology Co., Ltd.
67 patents
Oncotherapy Science, Inc.
67 patents
What this shows Oncotherapy holds 67 patents at rank #5,176, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #5,176 in granted patent volume.
Other assignees with the most granted patents in Oncotherapy's primary technology class.
Two PlainPatent-derived peer sets for Oncotherapy, neither rank-band nor same-CPC leaders (those blocks stay above). In A61K (Preparations FOR Medical), Oncotherapy ranks #331 of 7,163 assignees by patent count in that subclass.
Nearest assignees by Innovation Score (37 here).
Nearest assignees by average claims per patent (10.1 here).
Oncotherapy's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
37 Top 44% higher than 56% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 23 | 34.3% |
| 2016 | 9 | 13.4% |
| 2017 | 12 | 17.9% |
| 2018 | 3 | 4.5% |
| 2019 | 3 | 4.5% |
| 2020 | 8 | 11.9% |
| 2021 | 3 | 4.5% |
| 2022 | 2 | 3.0% |
| 2023 | 3 | 4.5% |
| 2025partial year | 1 | 1.5% |
Top 15 of 16 technology areas
Overall rank by patents
#5,176
of 49,997 tracked assignees
37.1 out of 100
What to do with this data
Oncotherapy Science, Inc.'s patent record in context - here's where to go next.
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.